Basic Information
Kyma Therapeutics will advance programs targeting immunomodulatory targets identified by Pyxis, developing new targets for antibody cancer and autoimmune diseases.
Kyma Therapeutics
United States of America
unclear
May 25, 2021
--
--
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios